Sana Biotechnology Achieves Breakthrough in In Vivo Gene Editing of Hematopoietic Stem Cells Using Fusogen Technology
核心洞察
Sana Biotechnology published breakthrough research in Nature Biotechnology demonstrating potent in vivo gene editing of hematopoietic stem cells in bone marrow using their fusogen technology platform.
The virus-like particle delivery system achieved cell-specific targeting of HSCs while avoiding off-target delivery to hepatocytes, potentially eliminating the need for conditioning chemotherapy.
This advancement broadens fusogen technology applications beyond T cells (搜索) to HSCs, with potential to transform treatment of sickle cell disease (搜索) and beta thalassemia (搜索).
Sana Biotechnology has achieved a significant breakthrough in gene therapy with the publication of research in Nature Biotechnology demonstrating successful in vivo gene editing of hematopoietic stem cells (HSCs) using their proprietary fusogen technology. The study, titled "In vivo gene editing of human hematopoietic stem and progenitor cells using envelope-engineered virus-like particles," shows potent and cell-specific gene editing of HSCs in bone marrow across multiple murine models.
Revolutionary Approach to HSC Gene Editing
The research evaluated a systemically delivered virus-like particle (VLP) using Sana's fusogen technology to target and gene edit HSCs in vivo. Results demonstrated stable gene-editing of long-term HSCs with remarkable specificity, addressing a critical challenge in the field of gene therapy.
"The fusogen technology has now shown the potential to offer cell-specific, in vivo delivery of various payloads into multiple cell types, and we believe it can be an important technology to treat a variety of diseases," said Dhaval Patel, MD, PhD, Sana's Chief Scientific Officer.
Overcoming Current Treatment Limitations
In vivo gene editing of HSCs represents a potential paradigm shift for treating diseases involving these crucial progenitor cells, particularly sickle cell disease (搜索) and beta thalassemia (搜索). Current treatment approaches face significant limitations, including the need for high doses of conditioning chemotherapy with associated risks of severe infections and secondary cancers, complex manufacturing processes, and prolonged hospitalization.
The fusogen platform addresses these challenges by efficiently reaching long-term multipotent HSCs in their natural bone marrow niche while avoiding off-target delivery to organs such as the liver. This precision targeting capability enables delivery of gene-editing and base-editing reagents to clinically relevant loci in human HSCs without the complications associated with traditional approaches.
Key Scientific Achievements
The publication highlighted several critical findings that demonstrate the technology's therapeutic potential:
- Optimized VLP enables potent in vivo editing in long-term human HSCs and editing of two hemoglobinopathy-relevant loci, including fetal hemoglobin
- Gene-editing VLP with targeted fusogen technology avoids off-target delivery to hepatocytes with systemic delivery
These results expand the fusogen technology's applications beyond its previous demonstration in CD8 (搜索)+ T cells (搜索), where the company showed the ability to specifically deliver genetic material to make in vivo CAR T cells while avoiding delivery to liver and gonadal tissues.
Clinical Development Pipeline
Sana is incorporating its fusogen technology to develop SG293 (搜索), a CD8 (搜索)-targeted fusosome that creates CD19 (搜索)-directed CAR T cells (搜索) in vivo. The company expects to file an investigational new drug (IND) application for SG293 in B-cell cancers (搜索) and/or B-cell mediated autoimmune diseases (搜索) as early as 2027.
The technology platform's versatility in delivering diverse payloads, including CRISPR gene-editing and base-editing machinery, positions it to address multiple therapeutic areas. According to Patel, this publication "broadens the diseases we can target with the potential to deliver transformative clinical impact, significantly reduced side effects through the elimination of conditioning chemotherapy, and a simplified supply chain."
Technology Platform Expansion
The fusogen technology's ability to deliver various payloads into multiple cell types represents a significant advancement in precision medicine. The platform has now demonstrated efficacy in two distinct cell types - T cells (搜索) and HSCs - suggesting broad applicability across different therapeutic targets and disease areas.
This cell-specific delivery capability addresses one of the most challenging aspects of gene therapy: achieving targeted delivery while minimizing off-target effects. The technology's success in avoiding hepatocyte delivery during systemic administration represents a crucial safety advantage that could accelerate clinical translation.